JP2021104931A - 含窒素複素環を有するジベンゾアゼピン誘導体 - Google Patents

含窒素複素環を有するジベンゾアゼピン誘導体 Download PDF

Info

Publication number
JP2021104931A
JP2021104931A JP2018029988A JP2018029988A JP2021104931A JP 2021104931 A JP2021104931 A JP 2021104931A JP 2018029988 A JP2018029988 A JP 2018029988A JP 2018029988 A JP2018029988 A JP 2018029988A JP 2021104931 A JP2021104931 A JP 2021104931A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
compound according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018029988A
Other languages
English (en)
Japanese (ja)
Inventor
渡辺　仁
Hitoshi Watanabe
仁 渡辺
磯部　義明
Yoshiaki Isobe
義明 磯部
恭次 石田
Kyoji Ishida
恭次 石田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Priority to JP2018029988A priority Critical patent/JP2021104931A/ja
Priority to PCT/JP2019/006455 priority patent/WO2019163865A1/fr
Publication of JP2021104931A publication Critical patent/JP2021104931A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018029988A 2018-02-22 2018-02-22 含窒素複素環を有するジベンゾアゼピン誘導体 Pending JP2021104931A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2018029988A JP2021104931A (ja) 2018-02-22 2018-02-22 含窒素複素環を有するジベンゾアゼピン誘導体
PCT/JP2019/006455 WO2019163865A1 (fr) 2018-02-22 2019-02-21 Dérivé de dibenzazépine ayant un cycle hétérocyclique contenant de l'azote

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018029988A JP2021104931A (ja) 2018-02-22 2018-02-22 含窒素複素環を有するジベンゾアゼピン誘導体

Publications (1)

Publication Number Publication Date
JP2021104931A true JP2021104931A (ja) 2021-07-26

Family

ID=67687734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018029988A Pending JP2021104931A (ja) 2018-02-22 2018-02-22 含窒素複素環を有するジベンゾアゼピン誘導体

Country Status (2)

Country Link
JP (1) JP2021104931A (fr)
WO (1) WO2019163865A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021463A2 (fr) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Analogues de diaryl[a,d]cycloheptène à substitution amino, utilisés comme agonistes muscariniques et méthodes de traitement de troubles neuropsychiatriques
US7550454B2 (en) * 2003-12-22 2009-06-23 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
CA2599922A1 (fr) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Utilisation de n-desmethylclozapine et de composes associes comme agents stabilisateurs de dopamine
TW201831462A (zh) * 2017-01-25 2018-09-01 日商大日本住友製藥股份有限公司 二苯并二氮呯衍生物

Also Published As

Publication number Publication date
WO2019163865A1 (fr) 2019-08-29

Similar Documents

Publication Publication Date Title
KR20220012924A (ko) 글루카곤-유사 펩티드 1 수용체 효능제
TWI543974B (zh) 苯基－３－氮雜－雙環［３．１．０］己－３－基－甲酮及其作為藥物之用途
CA2402751C (fr) Decahydro-isoquinolines
JP2020516666A (ja) アポトーシス誘発剤
JP2015514073A (ja) スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用
JP2010521528A (ja) Ｃｎｓ活性化合物としてのインドリジン及びそのアザ類似誘導体
Floyd et al. Benzazepinone calcium channel blockers. 2. Structure activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinones
CZ1698A3 (cs) Deriváty benzo/g/chinolinu, způsob jejich přípravy, farmaceutický prostředek, který je obsahuje a jejich použití
NZ526150A (en) Serotonergic agents
KR20130046436A (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도
WO2006090272A1 (fr) Isoquinoline [1,8]naphthyridin-2-ones et composes relatifs destines au traitement de la schizophrenie
JP5465716B2 (ja) Ｎｋ１受容体アンタゴニストとしての５−［５−［２−（３，５−ビス（トリフルオロメチル）フェニル）−２−メチルプロパノイルメチルアミノ］−４−（４−フルオロ−２−メチルフェニル）］−２−ピリジニル−２−アルキル−プロリンアミド
EP3373931A1 (fr) Composés hétérocycliques pour le traitement de maladies
DE602005006018T2 (de) Arylpiperazinderivate und deren verwendung als für den dopamin-d3-rezeptor selektive liganden
EP3204374B1 (fr) Dérivés d'isoindoline
TW201002702A (en) Dibenzothiazepine derivatives and uses thereof
JP7097342B2 (ja) ２，６－ジ置換ピリジン誘導体
JPH0225481A (ja) ２―［（４―ピペリジニル）メチル］―１，２，３，４―テトラヒドロイソキノリン誘導体、その製造方法およびその治療への適用
WO2018139471A1 (fr) Dérivé de dibenzodiazépine
JP2021104931A (ja) 含窒素複素環を有するジベンゾアゼピン誘導体
US4402956A (en) 2-[3-[4-(3-Chloro-4-fluorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one
New et al. Atypical antipsychotic agents: patterns of activity in a series of 3-substituted 2-pyridinyl-1-piperazine derivatives
CS248020B2 (en) Production method of the (+)-enantiomere or (+-)-racemical 4a,9b-trans-hexahydro-1h-pyridoindole derivatives
TW202204343A (zh) 經取代之３－苯氧基氮雜環丁烷－１－基－吡
JP2020055752A (ja) ジベンゾジアゼピン誘導体